Evidence map›Paper›PMID 41410942›Full record

ReviewJournal of cancer research and clinical oncology2025

Unveiling hidden players: the role of intratumoral microbiota in gastrointestinal cancer dynamics.

Wanfen Tang, Fakai Li, Hongjuan Zheng, Shishi Zhou, Chenhui Li, Xifeng Xu, Jianfei Fu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wanfen TangDepartment of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renmin East Road, Jinhua, 321000, Zhejiang Province, China.
Fakai LiDepartment of Respiratory and Critical Care, Jinhua Guangfu Cancer Hospital, Jinhua, Zhejiang Province, China.
Hongjuan ZhengDepartment of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renmin East Road, Jinhua, 321000, Zhejiang Province, China.
Shishi ZhouDepartment of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renmin East Road, Jinhua, 321000, Zhejiang Province, China.
Chenhui LiDepartment of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renmin East Road, Jinhua, 321000, Zhejiang Province, China.
Xifeng XuDepartment of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renmin East Road, Jinhua, 321000, Zhejiang Province, China.
Jianfei FuDepartment of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renmin East Road, Jinhua, 321000, Zhejiang Province, China. 11218276@zju.edu.cn.

Funding

Science and Technology Bureau of Jinhua City 2022-4-215Science and Technology Bureau of Jinhua City 2023-4-066
6 · The paper itself

Abstract

The intratumoral microbiota has emerged as a critical modulator of gastrointestinal (GI) tumour pathogenesis, influencing cancer initiation, progression, and treatment response. Recent studies have revealed that tumour-resident microbes, such as Fusobacterium nucleatum (F. nucleatum) and Bacteroides fragilis, contribute to metabolic reprogramming, immune evasion, and metastatic spread via mechanisms including microbiota-derived metabolites, induction of epithelial-mesenchymal transition, and conditioning of the premetastatic niche. Advances in multiomics technologies have enabled the precise characterization of microbial composition and function within the tumour microenvironment, revealing prognostic and predictive microbial signatures. Furthermore, emerging evidence highlights the potential of targeting the intratumoral microbiota to enhance conventional therapies and immunotherapies. This review summarizes key developments in understanding the role of the intratumoral microbiota in GI cancers and discusses future directions for translating these insights into clinical applications.

Indexed as

Gastrointestinal MicrobiomeGastrointestinal NeoplasmsMicrobiotaAnimalsEpithelial-Mesenchymal TransitionHumansTumor MicroenvironmentGastrointestinal cancerIntratumoral microbiotaTumour microenvironment

Identifiers

PMID41410942
PMCPMC12715092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.